Refractory lactotroph adenomas.

Authors:
Urwyler SA; Karavitaki N.

Journal:
Pituitary

Publication Year: 2023

DOI:
10.1007/s11102-023-01305-8

PMCID:
PMC10333396

PMID:
36928728

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Pituitary

Abbreviation: Pituitary

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Endocrinology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Care trajectories of surgically treated patients with a prolactinoma: why did they opt for surgery?
van Trigt VR; Zandbergen IM; Pelsma ICM and 4 more (2023) - Transparency Score: 2/6
Characteristics of inflammatory and infectious diseases of the pituitary gland in patients undergoi…
Naser PV; Papadopoulou P; Teuber J and 4 more (2023) - Transparency Score: 3/6
Complications and mortality of Cushing's disease: report on data collected over a 20-year period at…
Mondin A; Ceccato F; Voltan G and 5 more (2023) - Transparency Score: 3/6
Consensus on criteria for acromegaly diagnosis and remission.
Giustina A; Biermasz N; Casanueva FF and 7 more (2023) - Transparency Score: 3/6
Differences in clinical, hormonal, and radiological presentation and in surgical outcomes in patien…
Araujo-Castro M; Paredes I; Pérez-López C and 7 more (2023) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Conflict of interestSU was supported by a grant from the Swiss National Foundation (P2BSP3_191745). SU has no competing interests to declare that are relevant to the content of this article. NK has received honoraria and research funding from Pfizer. Conflict of interest SU was supported by a grant from the Swiss National Foundation (P2BSP3_191745). SU has no competing interests to declare that are relevant to the content of this article. NK has received honoraria and research funding from Pfizer."

Evidence found in paper:

"Declarations: Conflict of interestSU was supported by a grant from the Swiss National Foundation (P2BSP3_191745). SU has no competing interests to declare that are relevant to the content of this article. NK has received honoraria and research funding from Pfizer. Conflict of interest: SU was supported by a grant from the Swiss National Foundation (P2BSP3_191745). SU has no competing interests to declare that are relevant to the content of this article. NK has received honoraria and research funding from Pfizer."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025